#USA #Hong Kong #Ascletis #Obesity Treatment #ASC30_39

Ascletis Takes a Significant Step for Obesity Treatment

Ascletis Pharma Inc. has made headlines with its recent submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for an innovative therapeutic, ASC30_39 FDC. This potential first-in-class oral small molecule fixed-dose combination (FDC) integrates a GLP-1 receptor agonist, ASC30, and a selective amylin receptor agonist, ASC39, into a single tablet taken once daily. This marks a significant milestone in the field of obesity treatment, as it merges two established mechanisms known for their efficacy in managing weight into one convenient oral medication.

A Pioneering Combination Therapy

Dr. Jinzi Jason Wu, Founder, Chairman, and CEO of Ascletis, remarked on the submission, noting that ASC30_39 FDC is the first oral combination product that combines GLP-1 and amylin in a single formulation. This unique combination is believed to leverage the advantages of both agents, potentially enhancing weight management efficacy while maintaining gastrointestinal tolerability. Such characteristics are crucial for the adoption of obesity therapies, as patient compliance can often be a hurdle.

Both ASC30 and ASC39 were developed in-house using Ascletis' proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) technology, showcasing the company’s innovative approach to drug development. The combination product is engineered to ensure excellent compatibility, demonstrating stable properties that enable it to be stored effectively at room temperature with a manageable pill size.

Clinical Insights and Expectations

ASC30 has already gained considerable traction, having been evaluated in two pivotal Phase III studies—AURORA-1 and AURORA-2—with around 4,600 participants enrolled across the U.S., Europe, and Canada. Initial results highlight ASC30's favorable gastrointestinal tolerability, showcasing a lower incidence of side effects such as vomiting compared to existing treatments, thus positioning it as a promising candidate in the therapeutic landscape of obesity.

Moreover, ASC39 has showcased impressive targeted selectivity and efficacy in preclinical models, exhibiting an enhanced profile that could translate to effective weight loss outcomes in patients. Specifically, ASC39 demonstrated a significant body weight reduction in diet-induced obese rats, akin to established treatments, thereby reinforcing the anticipated benefits of this combination.

Future Implications

The implications of this IND application extend far beyond merely the launch of a new drug. If successful in clinical trials and subsequent regulatory reviews, ASC30_39 FDC could revolutionize the approach to managing obesity by providing a new, effective, and patient-friendly oral treatment option. The advent of such innovative therapies is timely, given the global obesity crisis and the urgent need for effective management strategies that encourage adherence to treatment regimens.

Ascletis aims to announce the topline data from the AURORA-1 and AURORA-2 studies in 2028, which could further highlight the clinical potential of ASC30 as a leading obesity treatment. As the biopharmaceutical landscape continues to shift towards innovative combination therapies, ASC30_39 FDC embodies a significant advancement in the quest for effective obesity interventions.

Conclusion

With the FDA's evaluation of this IND application underway, the healthcare community and patients alike are hopeful for the potential approval of ASC30_39 FDC. The work by Ascletis Pharma exemplifies the fusion of cutting-edge drug development with patient-centric solutions, reinforcing its position as a pioneer in obesity and metabolic disease therapeutics.